Abbott Laboratories said on Monday it and DexCom have reached an agreement to settle all patent disputes between the ...

Abbott Laboratories is rated a Buy due to growth indicators, diversified portfolio, strong profit margin. Read an investment ...

Shares of Abbott Laboratories ABT inched 0.39% higher to $114.76 Tuesday, on what proved to be an all-around positive trading ...

In a report released on December 20, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

"Abbott Laboratories began its 125th year with approximately ... "For our shareholders, we are developing the kind of essential, life-enhancing products that will ensure the enduring growth ...

Abbott is one of the biggest healthcare companies in the world. With over 400 consecutive quarterly dividend payouts and 53 ...

In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a price ...

Abbott (ABT) ended the recent trading session at $114.76, demonstrating a +0.39% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 1.1%.

Abbott Laboratories' board has raised the quarterly dividend by 7.3%, to 59 cents, making it 53 straight years that the healthcare-products company has boosted its payout. The new quarterly rate, ...

M&T Bank Corp lessened its holdings in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 6.3% during the 3rd quarter, ...

Abbott Laboratories has established itself as a ... with price targets ranging from $125 to $149. Abbott's diverse product portfolio has been a key driver of its success. The company has ...